Program
Lamotrigine
Also written as “lamotrigine”, “Lamotrigine Tablets 25 mg” and “Lamictal”.
Its studies are mostly in Epilepsy · Bipolar Disorder · Epilepsy, Tonic-Clonic · Epilepsies, Partial · Schizophrenia, led by 9 companies.
Drug pageLamotrigine: every studyMany companies study it; this page follows only the 54 they lead. All 137 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 330 open or running | phase 4since Aug 14, 2002 | Aug 14, 2002 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 80 open or running | phase 1since May 26, 2010 | May 26, 2010 | none ahead |
| Teva Pharmaceutical Industriesits history only | 40 open or running | phase 1since Jan 30, 2009 | Jan 30, 2009 | none ahead |
| IPCA Laboratoriesits history only | 20 open or running | phase 1since Jun 11, 2012 | Jun 11, 2012 | none ahead |
| Torrent Pharmaceuticalsits history only | 20 open or running | phase 1since Jul 13, 2009 | Jul 13, 2009 | none ahead |
| Viatrisits history only | 20 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| Alembic Pharmaceuticalsits history only | 10 open or running | phase 1since Jan 9, 2018 | Jan 9, 2018 | none ahead |
| Desitin Arzneimittelits history only | 10 open or running | phase 1since Dec 12, 2023 | Dec 12, 2023 | none ahead |
| Pharmtechnologyits history only | 10 open or running | phase 1since Mar 29, 2019 | Mar 29, 2019 | none ahead |
Also a collaborator on its studies: BioPharma Services.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of GlaxoSmithKline only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 18 studies since Aug 14, 2002.
- Aug 13, 2007Phase 3 study in EpilepsyNCT00516139 · 122 enrolled · United States
- Oct 26, 2007Phase 3 study in Bipolar DisorderNCT00550407 · 215 enrolled · Japan
- Nov 28, 2007Phase 3 study in Bipolar DisorderNCT00566020 · 92 enrolled · Japan
- Dec 20, 2007Phase 3 study in Mood DisordersNCT00579982 · 97 enrolled · United States
- Jan 18, 2008Phase 1 study in EpilepsyNCT00605371 · 209 enrolled · United States
- Feb 20, 2008Phase 1 study in EpilepsyNCT00627575 · 119 enrolled · United States
- Jul 24, 2008Phase 3 study in Bipolar DisorderNCT00723450 · 301 enrolled · United States
- May 12, 2011Phase 1 study in EpilepsyNCT01357902 · 24 enrolled · Hong Kong
- Sep 1, 20112 phase 3 studies in EpilepsyNCT01431976, NCT01431963
- May 17, 2012Phase 3 study in Bipolar DisorderNCT01602510 · 265 enrolled · China
- Jun 13, 2013Phase 1 study in EpilepsyNCT01879423 · 24 enrolled · China
- Feb 13, 2014Phase 1 study in EpilepsyNCT02064465 · 138 enrolled · China
- Mar 27, 2014Phase 4 study in EpilepsyNCT02100644 · 33 enrolled · Japan
- Jul 30, 2015Phase 1 study in Bipolar DisorderNCT02513654 · 16 enrolled · China
TargetBeta
“Sodium channel alpha subunit blocker”ChEMBL 37, by rule
Other programs on the same 10 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lidocainerule | Keenova Therapeutics | phase 4 | 63 |
| Carbamazepinerule | grin-therapeutics-inc | phase 4 | 21 |
| Dronedaronerule | Sanofi | phase 4 | 18 |
| chloroprocainerule | sintetica-sa | phase 4 | 8 |
| Riluzolerule | Sanofi | phase 4 | 6 |
| Prilocainerule | Haisco Pharmaceutical Group | phase 4 | 2 |
| Carticainerule | Laboratoires Thea | phase 4 | 1 |
| Ropivacainerule | painreform-ltd | phase 3 | 17 |
| Quinidinerule | Otsuka | phase 3 | 17 |
| Phenytoinrule | Viatris | phase 3 | 10 |
| rufinamiderule | Eisai | phase 3 | 7 |
Studies
All 33 GlaxoSmithKline leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02513654Bipolar Disorder · China | 1 | Completed | Nov 11, 2015 | 16 |
| NCT02100644Epilepsy · Japan | 4 | Completed | May 11, 2015 | 33 |
| NCT02064465Epilepsy · China | 1 | Completed | Jul 8, 2014 | 138 |
| NCT01879423Epilepsy · China | 1 | Completed | Jun 6, 2013 | 24 |
| NCT01602510Bipolar Disorder · China | 3 | Completed | Dec 2015 | 265 |
| NCT01431976Epilepsy · Japan, Korea, Republic of | 3 | Completed | Feb 2014 | 20 |
| NCT01431963Epilepsy · Japan, Korea, Republic of | 3 | Completed | Mar 2013 | 70 |
| NCT01357902Epilepsy · Hong Kong | 1 | Completed | May 23, 2011 | 24 |
| NCT00723450Bipolar Disorder · United States | 3 | Completed | Aug 2013 | 301 |
| NCT00627575Epilepsy · United States | 1 | Completed | Sep 12, 2008 | 119 |
| NCT00605371Epilepsy · United States | 1 | Completed | Mar 6, 2008 | 209 |
| NCT00579982Mood Disorders · United States | 3 | Completed | Feb 2008 | 97 |
| NCT00566020Bipolar Disorder · Japan | 3 | Completed | Oct 2010 | 92 |
| NCT00550407Bipolar Disorder · Japan | 3 | Completed | Oct 2009 | 215 |
| NCT00516139Epilepsy · United States | 3 | Completed | Jul 2010 | 122 |
| NCT00449774Mental Disorders · United States | 1 | Completed | Jun 19, 2007 | 220 |
| NCT00412191Epilepsy · Germany | 1 | Completed | Apr 27, 2007 | 180 |
| NCT00395694Epilepsy · Japan | 3 | Completed | Mar 1, 2009 | 102 |
| NCT00360126Bipolar Disorder · Australia | 4 | Completed | Feb 2007 | 11 |
| NCT00355082Epilepsies, Partial · United States, Argentina, Chile and more | 3 | Completed | Nov 2008 | 226 |
| NCT00264615Epilepsy · United States | 3 | Completed | Jun 2006 | 45 |
| NCT00224510Bipolar Disorder · Netherlands, Spain | 3 | Completed | Sep 2006 | 120 |
| NCT00144872Seizures · United States | 1 | Completed | Apr 22, 2006 | 54 |
| NCT00113165Epilepsy · United States, Argentina, Brazil and more | 3 | Completed | Jul 2007 | 244 |
| NCT00104416Epilepsy, Tonic-Clonic · United States, Argentina, Brazil and more | 3 | Completed | Jul 2008 | 153 |
| NCT00086593Schizophrenia · United States, Canada, United Kingdom | 3 | Completed | Jul 2005 | 209 |
| NCT00071747Schizophrenia · United States | 3 | Completed | 176 | |
| NCT00067938Bipolar Disorder · United States | 4 | Completed | Aug 2004 | 1,200 |
| NCT00056277Bipolar Disorder · United States | 3 | Completed | Aug 1, 2005 | 150 |
| NCT00044278Epilepsy · United States, Argentina, Australia and more | 2 | Completed | Jun 2006 | 197 |
| NCT00043914Epilepsy | 4 | Completed | Jan 29, 2003 | 72 |
| NCT00043901Epilepsy, Tonic-Clonic · United States, Argentina, Chile and more | 4 | Completed | Nov 1, 2003 | 141 |
| NCT00043875Epilepsy · United States, Australia, Estonia and more | 2 | Completed | Nov 2003 | 177 |
How it is read
Names in the registry
- “Lamotrigine”, 26 entries
- “lamotrigine”, 12 entries
- “Lamotrigine Tablets 25 mg”, 4 entries
- “Lamictal”, 3 entries
- “Lamotrigine 25 mg Chewable Tablets”, 2 entries
Conditions, from the studies’ own filings
- Epilepsy, 17 studies
- Bipolar Disorder, 11 studies
- Epilepsy, Tonic-Clonic, 2 studies
- Epilepsies, Partial, 2 studies
- Schizophrenia, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.